Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy

References

• Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689–701. doi:10.1016/S0140-6736(18)32596-0
   PubMed Web of Science ®Google Scholar
• Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15(1):245. doi:10.1186/s12883-015-0494-y
   PubMed Web of Science ®Google Scholar
• Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380(9848):1180–1192.
   PubMed Web of Science ®Google Scholar
• Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106–115. doi:10.1016/S1474-4422(15)00225-2
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521. doi:10.1111/epi.13709
   PubMed Web of Science ®Google Scholar
• Klein P, Dingledine R, Aronica E, et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia. 2018;59(1):37–66.
   PubMed Web of Science ®Google Scholar
• Pitkanen A, Lukasiuk K, Dudek FE, Staley KJ. Epileptogenesis. Cold Spring Harb Perspect Med. 2015;5(10):a022822. doi:10.1101/cshperspect.a022822
   PubMed Web of Science ®Google Scholar
• Henshall DC, Kobow K. Epigenetics and epilepsy. Cold Spring Harb Perspect Med. 2015;5(12). doi:10.1101/cshperspect.a022731
   PubMed Web of Science ®Google Scholar
• Thom M. Review: hippocampal sclerosis in epilepsy: a neuropathology review. Neuropathol Appl Neurobiol. 2014;40(5):520–543. doi:10.1111/nan.12150
   PubMed Web of Science ®Google Scholar
• Dogan E, Aygun H, Arslan G, et al. The role of NMDA receptors in the effect of purinergic P2X7 receptor on spontaneous seizure activity in WAG/Rij rats with genetic absence epilepsy. Front Neurosci. 2020;14:414. doi:10.3389/fnins.2020.00414
   PubMed Web of Science ®Google Scholar
• Engel T, Alves M, Sheedy C, Henshall DC. ATPergic signalling during seizures and epilepsy. Neuropharmacology. 2016;104:140–153. doi:10.1016/j.neuropharm.2015.11.001
   PubMed Web of Science ®Google Scholar
• Moshe SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet. 2015;385(9971):884–898. doi:10.1016/S0140-6736(14)60456-6
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68–82. doi:10.1038/nrd2997
   PubMed Web of Science ®Google Scholar
• Cross JH, Lagae L. The concept of disease modification. Eur J Paediatr Neurol. 2020;24:43–46. doi:10.1016/j.ejpn.2019.12.005
   PubMed Web of Science ®Google Scholar
• Loscher W. The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments. Neuropharmacology. 2020;167:107605. doi:10.1016/j.neuropharm.2019.04.011
   PubMed Web of Science ®Google Scholar
• Burnstock G. Purinergic signalling and neurological diseases: an update. CNS Neurol Disord Drug Targets. 2017;16(3):257–265. doi:10.2174/1871527315666160922104848
   PubMed Web of Science ®Google Scholar
• Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87(2):659–797.
   PubMed Web of Science ®Google Scholar
• Boison D. Adenosinergic signaling in epilepsy. Neuropharmacology. 2016;104:131–139. doi:10.1016/j.neuropharm.2015.08.046
   PubMed Web of Science ®Google Scholar
• Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 2018;3(Suppl 2):114–119. doi:10.1002/epi4.12268
   PubMedGoogle Scholar
• Coulter DA, Steinhauser C. Role of astrocytes in epilepsy. Cold Spring Harb Perspect Med. 2015;5(3):a022434. doi:10.1101/cshperspect.a022434
   PubMed Web of Science ®Google Scholar
• Hiragi T, Ikegaya Y, Koyama R. Microglia after seizures and in epilepsy. Cells. 2018;7(4):26. doi:10.3390/cells7040026
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15(8):459–472. doi:10.1038/s41582-019-0217-x
   PubMed Web of Science ®Google Scholar
• Verhoog QP, Holtman L, Aronica E, van Vliet EA. Astrocytes as guardians of neuronal excitability: mechanisms underlying epileptogenesis. Front Neurol. 2020;11:591690.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013;36(3):174–184. doi:10.1016/j.tins.2012.11.008
   PubMed Web of Science ®Google Scholar
• Xu S, Sun Q, Fan J, et al. Role of astrocytes in post-traumatic epilepsy. Front Neurol. 2019;10:1149. doi:10.3389/fneur.2019.01149
   PubMed Web of Science ®Google Scholar
• Walrave L, Vinken M, Leybaert L, Smolders I. Astrocytic connexin43 channels as candidate targets in epilepsy treatment. Biomolecules. 2020;10(11):1578. doi:10.3390/biom10111578
   PubMed Web of Science ®Google Scholar
• Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol. 2008;84(3):249–262. doi:10.1016/j.pneurobio.2007.12.002
   PubMed Web of Science ®Google Scholar
• Robel S, Buckingham SC, Boni JL, et al. Reactive astrogliosis causes the development of spontaneous seizures. J Neurosci. 2015;35(8):3330–3345. doi:10.1523/JNEUROSCI.1574-14.2015
   PubMed Web of Science ®Google Scholar
• Bilbo S, Stevens B. Microglia: the brain’s first responders. Cerebrum. 2017;2017.
   Google Scholar
• Kinoshita S, Koyama R. Pro- and anti-epileptic roles of microglia. Neural Regen Res. 2021;16(7):1369–1371. doi:10.4103/1673-5374.300976
   PubMed Web of Science ®Google Scholar
• Vezzani A, Conti M, De Luigi A, et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci. 1999;19(12):5054–5065. doi:10.1523/JNEUROSCI.19-12-05054.1999
   PubMed Web of Science ®Google Scholar
• Badimon A, Strasburger HJ, Ayata P, et al. Negative feedback control of neuronal activity by microglia. Nature. 2020;586(7829):417–423. doi:10.1038/s41586-020-2777-8
   PubMed Web of Science ®Google Scholar
• Zhao XF, Liao Y, Alam MM, et al. Microglial mTOR is neuronal protective and antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. J Neurosci. 2020;40(40):7593–7608. doi:10.1523/JNEUROSCI.2754-19.2020
   PubMed Web of Science ®Google Scholar
• Liu M, Jiang L, Wen M, et al. Microglia depletion exacerbates acute seizures and hippocampal neuronal degeneration in mouse models of epilepsy. Am J Physiol Cell Physiol. 2020;319(3):C605–C610. doi:10.1152/ajpcell.00205.2020
   PubMed Web of Science ®Google Scholar
• Fernandes A, Miller-Fleming L, Pais TF. Microglia and inflammation: conspiracy, controversy or control? Cell Mol Life Sci. 2014;71(20):3969–3985. doi:10.1007/s00018-014-1670-8
   PubMed Web of Science ®Google Scholar
• Therajaran P, Hamilton JA, O’Brien TJ, Jones NC, Ali I. Microglial polarization in posttraumatic epilepsy: potential mechanism and treatment opportunity. Epilepsia. 2020;61(2):203–215. doi:10.1111/epi.16424
   PubMed Web of Science ®Google Scholar
• Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–1194. doi:10.1007/s12035-014-9070-5
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27(1):451–483. doi:10.1146/annurev.immunol.021908.132532
   PubMed Web of Science ®Google Scholar
• Huang M, Li Y, Wu K, et al. Paraquat modulates microglia M1/M2 polarization via activation of TLR4-mediated NF-kappaB signaling pathway. Chem Biol Interact. 2019;310:108743. doi:10.1016/j.cbi.2019.108743
   PubMed Web of Science ®Google Scholar
• Sano F, Shigetomi E, Shinozaki Y, et al. Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus. JCI Insight. 2021;6(9). doi:10.1172/jci.insight.135391
   Web of Science ®Google Scholar
• Shinozaki Y, Shibata K, Yoshida K, et al. Transformation of astrocytes to a neuroprotective phenotype by microglia via P2Y1 receptor downregulation. Cell Rep. 2017;19(6):1151–1164. doi:10.1016/j.celrep.2017.04.047
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–487. doi:10.1038/nature21029
   PubMed Web of Science ®Google Scholar
• Quintas C, Fraga S, Goncalves J, Queiroz G. P2Y receptors on astrocytes and microglia mediate opposite effects in astroglial proliferation. Purinergic Signal. 2011;7(2):251–263. doi:10.1007/s11302-011-9235-x
   PubMed Web of Science ®Google Scholar
• Cho KO, Lybrand ZR, Ito N, et al. Aberrant hippocampal neurogenesis contributes to epilepsy and associated cognitive decline. Nat Commun. 2015;6:6606. doi:10.1038/ncomms7606
   PubMed Web of Science ®Google Scholar
• Benson MJ, Manzanero S, Borges K. Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models. Epilepsia. 2015;56(6):895–905. doi:10.1111/epi.12960
   PubMed Web of Science ®Google Scholar
• Broekaart DWM, Anink JJ, Baayen JC, et al. Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression. Epilepsia. 2018;59(10):1931–1944. doi:10.1111/epi.14550
   PubMed Web of Science ®Google Scholar
• Tian DS, Peng J, Murugan M, et al. Chemokine CCL2-CCR2 signaling induces neuronal cell death via STAT3 activation and IL-1beta production after status epilepticus. J Neurosci. 2017;37(33):7878–7892. doi:10.1523/JNEUROSCI.0315-17.2017
   PubMed Web of Science ®Google Scholar
• Feng L, Murugan M, Bosco DB, et al. Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus. Glia. 2019;67(8):1434–1448. doi:10.1002/glia.23616
   PubMed Web of Science ®Google Scholar
• Bosco DB, Tian DS, Wu LJ. Neuroimmune interaction in seizures and epilepsy: focusing on monocyte infiltration. FEBS J. 2020;287(22):4822–4837. doi:10.1111/febs.15428
   PubMed Web of Science ®Google Scholar
• Varvel NH, Neher JJ, Bosch A, et al. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. Proc Natl Acad Sci U S A. 2016;113(38):E5665–5674. doi:10.1073/pnas.1604263113
   PubMed Web of Science ®Google Scholar
• Wang S, Cheng Q, Malik S, Yang J. Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons. J Pharmacol Exp Ther. 2000;292(2):497–504.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu ZW, Wen L, Qiao HF, Zhou WX, Zhang YX. Interleukin-1beta enhances NMDA receptor-mediated current but inhibits excitatory synaptic transmission. Brain Res. 2005;1034(1–2):172–179. doi:10.1016/j.brainres.2004.11.018
   PubMed Web of Science ®Google Scholar
• Roseti C, van Vliet EA, Cifelli P, et al. GABAA currents are decreased by IL-1beta in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis. Neurobiol Dis. 2015;82:311–320. doi:10.1016/j.nbd.2015.07.003
   PubMed Web of Science ®Google Scholar
• Viviani B, Gardoni F, Marinovich M. Cytokines and neuronal ion channels in health and disease. Int Rev Neurobiol. 2007;82:247–263.
   PubMed Web of Science ®Google Scholar
• Yan J, Melemedjian OK, Price TJ, Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012;8:6. doi:10.1186/1744-8069-8-6
   PubMed Web of Science ®Google Scholar
• Wu Z, Wang S, Gruber S, Mata M, Fink DJ. Full-length membrane-bound tumor necrosis factor-alpha acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. Pain. 2013;154(9):1778–1782. doi:10.1016/j.pain.2013.05.038
   PubMed Web of Science ®Google Scholar
• Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015;96(Pt A):70–82. doi:10.1016/j.neuropharm.2014.10.027
   PubMedGoogle Scholar
• Huang KF, Huang WT, Lin KC, Lin MT, Chang CP. Interleukin-1 receptor antagonist inhibits the release of glutamate, hydroxyl radicals, and prostaglandin E(2) in the hypothalamus during pyrogen-induced fever in rabbits. Eur J Pharmacol. 2010;629(1–3):125–131. doi:10.1016/j.ejphar.2009.11.060
   PubMed Web of Science ®Google Scholar
• Rossi S, Furlan R, De Chiara V, et al. Interleukin-1beta causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012;71(1):76–83. doi:10.1002/ana.22512
   PubMed Web of Science ®Google Scholar
• Clarkson BDS, Kahoud RJ, McCarthy CB, Howe CL. Inflammatory cytokine-induced changes in neural network activity measured by waveform analysis of high-content calcium imaging in murine cortical neurons. Sci Rep. 2017;7(1):9037. doi:10.1038/s41598-017-09182-5
   PubMedGoogle Scholar
• Zhu G, Okada M, Yoshida S, et al. Effects of interleukin-1beta on hippocampal glutamate and GABA releases associated with Ca2+-induced Ca2+ releasing systems. Epilepsy Res. 2006;71(2–3):107–116. doi:10.1016/j.eplepsyres.2006.05.017
   PubMed Web of Science ®Google Scholar
• Gardoni F, Boraso M, Zianni E, et al. Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1beta and NMDA stimulation. J Neuroinflammation. 2011;8(1):14. doi:10.1186/1742-2094-8-14
   PubMedGoogle Scholar
• Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci. 2003;23(25):8692–8700. doi:10.1523/JNEUROSCI.23-25-08692.2003
   PubMed Web of Science ®Google Scholar
• Balosso S, Maroso M, Sanchez-Alavez M, et al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain. 2008;131(Pt 12):3256–3265. doi:10.1093/brain/awn271
   PubMed Web of Science ®Google Scholar
• Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 2005;25(12):3219–3228. doi:10.1523/JNEUROSCI.4486-04.2005
   PubMed Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010;16(4):413–419. doi:10.1038/nm.2127
   PubMed Web of Science ®Google Scholar
• Iori V, Iyer AM, Ravizza T, et al. Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiol Dis. 2017;99:12–23. doi:10.1016/j.nbd.2016.12.007
   PubMed Web of Science ®Google Scholar
• Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013;59:183–193. doi:10.1016/j.nbd.2013.07.015
   PubMed Web of Science ®Google Scholar
• French JA, Koepp M, Naegelin Y, et al. Clinical studies and anti-inflammatory mechanisms of treatments. Epilepsia. 2017;58(Suppl 3):69–82. doi:10.1111/epi.13779
   PubMed Web of Science ®Google Scholar
• Campos G, Fortuna A, Falcao A, Alves G. In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res. 2018;146:63–86.
   PubMed Web of Science ®Google Scholar
• Loscher W. Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res. 2017;42(7):1873–1888. doi:10.1007/s11064-017-2222-z
   PubMed Web of Science ®Google Scholar
• Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20(5):359–368. doi:10.1016/j.seizure.2011.01.003
   PubMed Web of Science ®Google Scholar
• Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008;172(2):143–157. doi:10.1016/j.jneumeth.2008.04.019
   PubMed Web of Science ®Google Scholar
• Marchi N, Oby E, Batra A, et al. In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia. 2007;48(10):1934–1946. doi:10.1111/j.1528-1167.2007.01185.x
   PubMed Web of Science ®Google Scholar
• Levesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2887–2899.
   PubMed Web of Science ®Google Scholar
• Welzel L, Schidlitzki A, Twele F, Anjum M, Loscher W. A face-to-face comparison of the intra-amygdala and intrahippocampal kainate mouse models of mesial temporal lobe epilepsy and their utility for testing novel therapies. Epilepsia. 2020;61(1):157–170. doi:10.1111/epi.16406
   PubMed Web of Science ®Google Scholar
• Conte G, Parras A, Alves M, et al. High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy. Epilepsia. 2020;61(12):2795–2810. doi:10.1111/epi.16714
   PubMed Web of Science ®Google Scholar
• Burnstock G. Purinergic nerves. Pharmacol Rev. 1972;24(3):509–581.
   PubMed Web of Science ®Google Scholar
• Rodrigues RJ, Tome AR, Cunha RA. ATP as a multi-target danger signal in the brain. Front Neurosci. 2015;9:148. doi:10.3389/fnins.2015.00148
   PubMed Web of Science ®Google Scholar
• Khakh BS, North RA. Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron. 2012;76(1):51–69. doi:10.1016/j.neuron.2012.09.024
   PubMed Web of Science ®Google Scholar
• Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature. 2014;509(7500):310–317. doi:10.1038/nature13085
   PubMed Web of Science ®Google Scholar
• Dale N, Frenguelli BG. Release of adenosine and ATP during ischemia and epilepsy. Curr Neuropharmacol. 2009;7(3):160–179. doi:10.2174/157015909789152146
   PubMed Web of Science ®Google Scholar
• Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826–837. doi:10.1038/nri2873
   PubMed Web of Science ®Google Scholar
• Lecca D, Ceruti S. Uracil nucleotides: from metabolic intermediates to neuroprotection and neuroinflammation. Biochem Pharmacol. 2008;75(10):1869–1881. doi:10.1016/j.bcp.2007.12.009
   PubMed Web of Science ®Google Scholar
• Zimmermann H. Ectonucleotidases in the nervous system. Novartis Found Symp. 2006;276:113–128; discussion 128–130, 233-117, 275-181.
   PubMedGoogle Scholar
• Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology. 2016;104:4–17.
   PubMed Web of Science ®Google Scholar
• Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006;442(7102):527–532. doi:10.1038/nature04886
   PubMed Web of Science ®Google Scholar
• North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82(4):1013–1067. doi:10.1152/physrev.00015.2002
   PubMed Web of Science ®Google Scholar
• Coddou C, Stojilkovic SS, Huidobro-Toro JP. Allosteric modulation of ATP-gated P2X receptor channels. Rev Neurosci. 2011;22(3):335–354. doi:10.1515/rns.2011.014
   PubMed Web of Science ®Google Scholar
• North RA, Jarvis MF. P2X receptors as drug targets. Mol Pharmacol. 2013;83(4):759–769. doi:10.1124/mol.112.083758
   PubMed Web of Science ®Google Scholar
• Pankratov Y, Lalo U, Krishtal OA, Verkhratsky A. P2X receptors and synaptic plasticity. Neuroscience. 2009;158(1):137–148. doi:10.1016/j.neuroscience.2008.03.076
   PubMed Web of Science ®Google Scholar
• Burnstock G. P2X ion channel receptors and inflammation. Purinergic Signal. 2016;12(1):59–67. doi:10.1007/s11302-015-9493-0
   PubMed Web of Science ®Google Scholar
• Beamer E, Fischer W, Engel T. The ATP-gated P2X7 receptor as a target for the treatment of drug-resistant epilepsy. Front Neurosci. 2017;11:21. doi:10.3389/fnins.2017.00021
   PubMed Web of Science ®Google Scholar
• Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47(1):15–31. doi:10.1016/j.immuni.2017.06.020
   PubMed Web of Science ®Google Scholar
• Barros-Barbosa AR, Fonseca AL, Guerra-Gomes S, et al. Up-regulation of P2X7 receptor-mediated inhibition of GABA uptake by nerve terminals of the human epileptic neocortex. Epilepsia. 2016;57(1):99–110. doi:10.1111/epi.13263
   PubMed Web of Science ®Google Scholar
• Barros-Barbosa AR, Oliveira A, Lobo MG, Cordeiro JM, Correia-de-sa P. Under stressful conditions activation of the ionotropic P2X7 receptor differentially regulates GABA and glutamate release from nerve terminals of the rat cerebral cortex. Neurochem Int. 2018;112:81–95. doi:10.1016/j.neuint.2017.11.005
   PubMed Web of Science ®Google Scholar
• Oliveira SD, Coutinho-Silva R, Silva CL. Endothelial P2X7 receptors’ expression is reduced by schistosomiasis. Purinergic Signal. 2013;9(1):81–89. doi:10.1007/s11302-012-9332-5
   PubMed Web of Science ®Google Scholar
• Zhao YF, Tang Y, Illes P. Astrocytic and oligodendrocytic P2X7 receptors determine neuronal functions in the CNS. Front Mol Neurosci. 2021;14:641570. doi:10.3389/fnmol.2021.641570
   PubMed Web of Science ®Google Scholar
• Illes P, Khan TM, Rubini P. Neuronal P2X7 receptors revisited: do they really exist? J Neurosci. 2017;37(30):7049–7062. doi:10.1523/JNEUROSCI.3103-16.2017
   PubMed Web of Science ®Google Scholar
• Miras-Portugal MT, Sebastian-Serrano A, de Diego Garcia L, Diaz-Hernandez M. Neuronal P2X7 receptor: involvement in neuronal physiology and pathology. J Neurosci. 2017;37(30):7063–7072. doi:10.1523/JNEUROSCI.3104-16.2017
   PubMed Web of Science ®Google Scholar
• von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther. 2006;110(3):415–432. doi:10.1016/j.pharmthera.2005.08.014
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Paoletta S, Katritch V, et al. Nucleotides acting at P2Y receptors: connecting structure and function. Mol Pharmacol. 2015;88(2):220–230. doi:10.1124/mol.114.095711
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Boeynaems JM. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today. 2010;15(13–14):570–578. doi:10.1016/j.drudis.2010.05.011
   PubMed Web of Science ®Google Scholar
• Guzman SJ, Gerevich Z. P2Y receptors in synaptic transmission and plasticity: therapeutic potential in cognitive dysfunction. Neural Plast. 2016;2016:1207393. doi:10.1155/2016/1207393
   PubMed Web of Science ®Google Scholar
• Inoue K. Purinergic systems in microglia. Cell Mol Life Sci. 2008;65(19):3074–3080. doi:10.1007/s00018-008-8210-3
   PubMed Web of Science ®Google Scholar
• Crain JM, Nikodemova M, Watters JJ. Expression of P2 nucleotide receptors varies with age and sex in murine brain microglia. J Neuroinflammation. 2009;6:24. doi:10.1186/1742-2094-6-24
   PubMed Web of Science ®Google Scholar
• Crain JM, Watters JJ. Microglial P2 purinergic receptor and immunomodulatory gene transcripts vary by region, sex, and age in the healthy mouse CNS. Transcr Open Access. 2015;3(2). doi:10.4172/2329-8936.1000124
   PubMedGoogle Scholar
• Abbracchio MP, Ceruti S. Roles of P2 receptors in glial cells: focus on astrocytes. Purinergic Signal. 2006;2(4):595–604. doi:10.1007/s11302-006-9016-0
   PubMedGoogle Scholar
• Florenzano F, Viscomi MT, Cavaliere F, Volonte C, Molinari M. Cerebellar lesion up-regulates P2X1 and P2X2 purinergic receptors in precerebellar nuclei. Neuroscience. 2002;115(2):425–434. doi:10.1016/S0306-4522(02)00397-4
   PubMed Web of Science ®Google Scholar
• Cavaliere F, Florenzano F, Amadio S, et al. Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience. 2003;120(1):85–98. doi:10.1016/S0306-4522(03)00228-8
   PubMed Web of Science ®Google Scholar
• Viscomi MT, Florenzano F, Conversi D, Bernardi G, Molinari M. Axotomy dependent purinergic and nitrergic co-expression. Neuroscience. 2004;123(2):393–404. doi:10.1016/j.neuroscience.2003.09.030
   PubMed Web of Science ®Google Scholar
• Franke H, Krugel U, Grosche J, et al. P2Y receptor expression on astrocytes in the nucleus accumbens of rats. Neuroscience. 2004;127(2):431–441. doi:10.1016/j.neuroscience.2004.05.003
   PubMed Web of Science ®Google Scholar
• Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F. The P2X7 receptor: a main player in inflammation. Biochem Pharmacol. 2018;151:234–244. doi:10.1016/j.bcp.2017.12.021
   PubMed Web of Science ®Google Scholar
• Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem. 2001;276(6):3820–3826. doi:10.1074/jbc.M006814200
   PubMed Web of Science ®Google Scholar
• Lu W, Albalawi F, Beckel JM, Lim JC, Laties AM, Mitchell CH. The P2X7 receptor links mechanical strain to cytokine IL-6 up-regulation and release in neurons and astrocytes. J Neurochem. 2017;141(3):436–448. doi:10.1111/jnc.13998
   PubMed Web of Science ®Google Scholar
• He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. J Neuroinflammation. 2017;14(1):135. doi:10.1186/s12974-017-0904-8
   PubMedGoogle Scholar
• Illes P, Verkhratsky A, Tang Y. Pathological ATPergic signaling in major depression and bipolar disorder. Front Mol Neurosci. 2019;12:331. doi:10.3389/fnmol.2019.00331
   PubMed Web of Science ®Google Scholar
• de Rivero Vaccari JP, Bastien D, Yurcisin G, et al. P2X4 receptors influence inflammasome activation after spinal cord injury. J Neurosci. 2012;32(9):3058–3066. doi:10.1523/JNEUROSCI.4930-11.2012
   PubMed Web of Science ®Google Scholar
• Engel T, Gomez‐Villafuertes R, Tanaka K, et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 2012;26(4):1616–1628. doi:10.1096/fj.11-196089
   PubMed Web of Science ®Google Scholar
• Adinolfi E, Capece M, Franceschini A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 2015;75(4):635–644. doi:10.1158/0008-5472.CAN-14-1259
   PubMed Web of Science ®Google Scholar
• Rodriguez-Alvarez N, Jimenez-Mateos EM, Engel T, et al. Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice. Neuropharmacology. 2017;116:351–363. doi:10.1016/j.neuropharm.2017.01.005
   PubMed Web of Science ®Google Scholar
• Albalawi F, Lu W, Beckel JM, Lim JC, McCaughey SA, Mitchell CH. The P2X7 receptor primes IL-1beta and the NLRP3 inflammasome in astrocytes exposed to mechanical strain. Front Cell Neurosci. 2017;11:227. doi:10.3389/fncel.2017.00227
   PubMed Web of Science ®Google Scholar
• Franceschini A, Capece M, Chiozzi P, et al. The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein. FASEB J. 2015;29(6):2450–2461. doi:10.1096/fj.14-268714
   PubMed Web of Science ®Google Scholar
• Abe T, Lee A, Sitharam R, Kesner J, Rabadan R, Shapira SD. Germ-cell-specific inflammasome component NLRP14 negatively regulates cytosolic nucleic acid sensing to promote fertilization. Immunity. 2017;46(4):621–634. doi:10.1016/j.immuni.2017.03.020
   PubMed Web of Science ®Google Scholar
• Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci. 2009;29(12):3781–3791. doi:10.1523/JNEUROSCI.5512-08.2009
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen Y, Feng H. P2X7 receptor-associated programmed cell death in the pathophysiology of hemorrhagic stroke. Curr Neuropharmacol. 2018;16(9):1282–1295. doi:10.2174/1570159X16666180516094500
   PubMed Web of Science ®Google Scholar
• Turola E, Furlan R, Bianco F, Matteoli M, Verderio C. Microglial microvesicle secretion and intercellular signaling. Front Physiol. 2012;3:149. doi:10.3389/fphys.2012.00149
   PubMed Web of Science ®Google Scholar
• Karasawa A, Michalski K, Mikhelzon P, Kawate T. The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition. Elife. 2017;6. doi:10.7554/eLife.31186
   PubMed Web of Science ®Google Scholar
• Bernier LP, Ase AR, Boue-Grabot E, Seguela P. P2X4 receptor channels form large noncytolytic pores in resting and activated microglia. Glia. 2012;60(5):728–737. doi:10.1002/glia.22301
   PubMed Web of Science ®Google Scholar
• Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol. 1997;139(7):1635–1643. doi:10.1083/jcb.139.7.1635
   PubMed Web of Science ®Google Scholar
• Ferrari D, Stroh C, Schulze-Osthoff K. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999;274(19):13205–13210. doi:10.1074/jbc.274.19.13205
   PubMed Web of Science ®Google Scholar
• Kamatsuka Y, Fukagawa M, Furuta T, Ohishi A, Nishida K, Nagasawa K. Astrocytes, but not neurons, exhibit constitutive activation of P2X7 receptors in mouse acute cortical slices under non-stimulated resting conditions. Biol Pharm Bull. 2014;37(12):1958–1962. doi:10.1248/bpb.b14-00000
   PubMed Web of Science ®Google Scholar
• Munoz FM, Patel PA, Gao X, et al. Reactive oxygen species play a role in P2X7 receptor-mediated IL-6 production in spinal astrocytes. Purinergic Signal. 2020;16(1):97–107. doi:10.1007/s11302-020-09691-5
   PubMed Web of Science ®Google Scholar
• Minkiewicz J, de Rivero Vaccari JP, Keane RW. Human astrocytes express a novel NLRP2 inflammasome. Glia. 2013;61(7):1113–1121. doi:10.1002/glia.22499
   PubMed Web of Science ®Google Scholar
• Ulmann L, Hatcher JP, Hughes JP, et al. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci. 2008;28(44):11263–11268. doi:10.1523/JNEUROSCI.2308-08.2008
   PubMed Web of Science ®Google Scholar
• Wixey JA, Reinebrant HE, Carty ML, Buller KM. Delayed P2X4R expression after hypoxia-ischemia is associated with microglia in the immature rat brain. J Neuroimmunol. 2009;212(1–2):35–43. doi:10.1016/j.jneuroim.2009.04.016
   PubMed Web of Science ®Google Scholar
• Vazquez-Villoldo N, Domercq M, Martin A, Llop J, Gomez-Vallejo V, Matute C. P2X4 receptors control the fate and survival of activated microglia. Glia. 2014;62(2):171–184. doi:10.1002/glia.22596
   PubMed Web of Science ®Google Scholar
• Kukley M, Barden JA, Steinhauser C, Jabs R. Distribution of P2X receptors on astrocytes in juvenile rat hippocampus. Glia. 2001;36(1):11–21. doi:10.1002/glia.1091
   PubMed Web of Science ®Google Scholar
• Jabs R, Matthias K, Grote A, Grauer M, Seifert G, Steinhauser C. Lack of P2X receptor mediated currents in astrocytes and GluR type glial cells of the hippocampal CA1 region. Glia. 2007;55(16):1648–1655. doi:10.1002/glia.20580
   PubMed Web of Science ®Google Scholar
• Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S. Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 2007;55(6):604–616. doi:10.1002/glia.20489
   PubMed Web of Science ®Google Scholar
• Montilla A, Mata GP, Matute C, Domercq M. Contribution of P2X4 receptors to CNS function and pathophysiology. Int J Mol Sci. 2020;21(15). doi:10.3390/ijms21155562
   PubMed Web of Science ®Google Scholar
• Ulmann L, Levavasseur F, Avignone E, et al. Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus. Glia. 2013;61(8):1306–1319. doi:10.1002/glia.22516
   PubMed Web of Science ®Google Scholar
• Raouf R, Chabot-Dore AJ, Ase AR, Blais D, Seguela P. Differential regulation of microglial P2X4 and P2X7 ATP receptors following LPS-induced activation. Neuropharmacology. 2007;53(4):496–504. doi:10.1016/j.neuropharm.2007.06.010
   PubMed Web of Science ®Google Scholar
• Masuda T, Iwamoto S, Yoshinaga R, et al. Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain. Nat Commun. 2014;5(1):3771. doi:10.1038/ncomms4771
   PubMedGoogle Scholar
• Kawai K, Baba S. Studies on drug metabolism by use of isotopes. XV. Stability of deuterium-label in p-hydroxylation of l-ephedrine. Chem Pharm Bull (Tokyo). 1975;23(4):920–922. doi:10.1248/cpb.23.920
   PubMed Web of Science ®Google Scholar
• Trang T, Beggs S, Wan X, Salter MW. P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J Neurosci. 2009;29(11):3518–3528. doi:10.1523/JNEUROSCI.5714-08.2009
   PubMed Web of Science ®Google Scholar
• Su WF, Wu F, Jin ZH, et al. Overexpression of P2X4 receptor in Schwann cells promotes motor and sensory functional recovery and remyelination via BDNF secretion after nerve injury. Glia. 2019;67(1):78–90. doi:10.1002/glia.23527
   PubMed Web of Science ®Google Scholar
• Zabala A, Vazquez-Villoldo N, Rissiek B, et al. P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis. EMBO Mol Med. 2018;10(8). doi:10.15252/emmm.201708743
   PubMed Web of Science ®Google Scholar
• Forster D, Reiser G. Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies. Purinergic Signal. 2015;11(4):441–454. doi:10.1007/s11302-015-9471-6
   PubMed Web of Science ®Google Scholar
• Carmo MR, Simoes AP, Fonteles AA, Souza CM, Cunha RA, Andrade GM. ATP P2Y1 receptors control cognitive deficits and neurotoxicity but not glial modifications induced by brain ischemia in mice. Eur J Neurosci. 2014;39(4):614–622. doi:10.1111/ejn.12435
   PubMed Web of Science ®Google Scholar
• Choo AM, Miller WJ, Chen YC, et al. Antagonism of purinergic signalling improves recovery from traumatic brain injury. Brain. 2013;136(Pt 1):65–80. doi:10.1093/brain/aws286
   PubMedGoogle Scholar
• Kuboyama K, Harada H, Tozaki-Saitoh H, Tsuda M, Ushijima K, Inoue K. Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia. J Cereb Blood Flow Metab. 2011;31(9):1930–1941. doi:10.1038/jcbfm.2011.49
   PubMed Web of Science ®Google Scholar
• Wellmann M, Alvarez-Ferradas C, Maturana CJ, Saez JC, Bonansco C. Astroglial Ca(2+)-dependent hyperexcitability requires P2Y1 purinergic receptors and pannexin-1 channel activation in a chronic model of epilepsy. Front Cell Neurosci. 2018;12:446. doi:10.3389/fncel.2018.00446
   PubMed Web of Science ®Google Scholar
• Fujita T, Tozaki-Saitoh H, Inoue K. P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. Glia. 2009;57(3):244–257. doi:10.1002/glia.20749
   PubMed Web of Science ®Google Scholar
• Quintas C, Fraga S, Goncalves J, Queiroz G. Opposite modulation of astroglial proliferation by adenosine 5ʹ-O-(2-thio)-diphosphate and 2-methylthioadenosine-5ʹ-diphosphate: mechanisms involved. Neuroscience. 2011;182:32–42. doi:10.1016/j.neuroscience.2011.03.009
   PubMed Web of Science ®Google Scholar
• Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6 Pt A):1218–1227. doi:10.1016/j.bbamcr.2016.03.018
   PubMed Web of Science ®Google Scholar
• Mildner A, Huang H, Radke J, Stenzel W, Priller J. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia. 2017;65(2):375–387. doi:10.1002/glia.23097
   PubMed Web of Science ®Google Scholar
• Irino Y, Nakamura Y, Inoue K, Kohsaka S, Ohsawa K. Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia. J Neurosci Res. 2008;86(7):1511–1519. doi:10.1002/jnr.21610
   PubMed Web of Science ®Google Scholar
• Dissing-Olesen L, LeDue JM, Rungta RL, Hefendehl JK, Choi HB, MacVicar BA. Activation of neuronal NMDA receptors triggers transient ATP-mediated microglial process outgrowth. J Neurosci. 2014;34(32):10511–10527. doi:10.1523/JNEUROSCI.0405-14.2014
   PubMed Web of Science ®Google Scholar
• Eyo UB, Peng J, Swiatkowski P, Mukherjee A, Bispo A, Wu LJ. Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J Neurosci. 2014;34(32):10528–10540. doi:10.1523/JNEUROSCI.0416-14.2014
   PubMed Web of Science ®Google Scholar
• Amadio S, Montilli C, Magliozzi R, Bernardi G, Reynolds R, Volonte C. P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis. Cereb Cortex. 2010;20(6):1263–1273. doi:10.1093/cercor/bhp193
   PubMed Web of Science ®Google Scholar
• Webster CM, Hokari M, McManus A, et al. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS One. 2013;8(8):e70927. doi:10.1371/journal.pone.0070927
   PubMed Web of Science ®Google Scholar
• Gomez Morillas A, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for P2RY12? Int J Mol Sci. 2021;22(4). doi:10.3390/ijms22041636
   PubMed Web of Science ®Google Scholar
• Quintas C, Pinho D, Pereira C, Saraiva L, Goncalves J, Queiroz G. Microglia P2Y(6) receptors mediate nitric oxide release and astrocyte apoptosis. J Neuroinflammation. 2014;11(1):141. doi:10.1186/s12974-014-0141-3
   PubMedGoogle Scholar
• Kyrargyri V, Madry C, Rifat A, et al. P2Y13 receptors regulate microglial morphology, surveillance, and resting levels of interleukin 1beta release. Glia. 2020;68(2):328–344. doi:10.1002/glia.23719
   PubMed Web of Science ®Google Scholar
• Bianco F, Fumagalli M, Pravettoni E, et al. Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res Brain Res Rev. 2005;48(2):144–156. doi:10.1016/j.brainresrev.2004.12.004
   PubMedGoogle Scholar
• Carrasquero LM, Delicado EG, Bustillo D, Gutierrez-Martin Y, Artalejo AR, Miras-Portugal MT. P2X7 and P2Y13 purinergic receptors mediate intracellular calcium responses to BzATP in rat cerebellar astrocytes. J Neurochem. 2009;110(3):879–889. doi:10.1111/j.1471-4159.2009.06179.x
   PubMed Web of Science ®Google Scholar
• Fischer W, Norenberg W, Franke H, Schaefer M, Illes P. Increase of intracellular Ca2+ by P2Y but not P2X receptors in cultured cortical multipolar neurons of the rat. J Comp Neurol. 2009;516(5):343–359. doi:10.1002/cne.22079
   PubMed Web of Science ®Google Scholar
• Zheng W, Talley Watts L, Holstein DM, Wewer J, Lechleiter JD. P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J Cereb Blood Flow Metab. 2013;33(4):600–611. doi:10.1038/jcbfm.2012.214
   PubMed Web of Science ®Google Scholar
• Liu PW, Yue MX, Zhou R, et al. P2Y12 and P2Y13 receptors involved in ADPbetas induced the release of IL-1beta, IL-6 and TNF-alpha from cultured dorsal horn microglia. J Pain Res. 2017;10:1755–1767. doi:10.2147/JPR.S137131
   PubMed Web of Science ®Google Scholar
• Milior G, Morin-Brureau M, Chali F, et al. Distinct P2Y receptors mediate extension and retraction of microglial processes in epileptic and peritumoral human tissue. J Neurosci. 2020;40(7):1373–1388. doi:10.1523/JNEUROSCI.0218-19.2019
   PubMed Web of Science ®Google Scholar
• Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007;446(7139):1091–1095. doi:10.1038/nature05704
   PubMed Web of Science ®Google Scholar
• Bernier LP, Ase AR, Boue-Grabot E, Seguela P. Inhibition of P2X4 function by P2Y6 UDP receptors in microglia. Glia. 2013;61(12):2038–2049. doi:10.1002/glia.22574
   PubMed Web of Science ®Google Scholar
• Chorna NE, Santiago-Perez LI, Erb L, et al. P2Y receptors activate neuroprotective mechanisms in astrocytic cells. J Neurochem. 2004;91(1):119–132. doi:10.1111/j.1471-4159.2004.02699.x
   PubMed Web of Science ®Google Scholar
• Wang M, Kong Q, Gonzalez FA, et al. P2Y nucleotide receptor interaction with alpha integrin mediates astrocyte migration. J Neurochem. 2005;95(3):630–640. doi:10.1111/j.1471-4159.2005.03408.x
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ajit D, Peterson TS, et al. Nucleotides released from Abeta(1)(-)(4)(2) -treated microglial cells increase cell migration and Abeta(1)(-)(4)(2) uptake through P2Y(2) receptor activation. J Neurochem. 2012;121(2):228–238. doi:10.1111/j.1471-4159.2012.07700.x
   PubMed Web of Science ®Google Scholar
• Wieraszko A, Seyfried TN. ATP-induced synaptic potentiation in hippocampal slices. Brain Res. 1989;491(2):356–359. doi:10.1016/0006-8993(89)90070-X
   PubMed Web of Science ®Google Scholar
• Wu PH, Phillis JW. Distribution and release of adenosine triphosphate in rat brain. Neurochem Res. 1978;3(5):563–571. doi:10.1007/BF00963759
   PubMed Web of Science ®Google Scholar
• Heinrich A, Ando RD, Turi G, Rozsa B, Sperlagh B. K+ depolarization evokes ATP, adenosine and glutamate release from glia in rat hippocampus: a microelectrode biosensor study. Br J Pharmacol. 2012;167(5):1003–1020. doi:10.1111/j.1476-5381.2012.01932.x
   PubMed Web of Science ®Google Scholar
• Lopatar J, Dale N, Frenguelli BG. Pannexin-1-mediated ATP release from area CA3 drives mGlu5-dependent neuronal oscillations. Neuropharmacology. 2015;93:219–228. doi:10.1016/j.neuropharm.2015.01.014
   PubMed Web of Science ®Google Scholar
• Lopatar J, Dale N, Frenguelli BG. Minor contribution of ATP P2 receptors to electrically-evoked electrographic seizure activity in hippocampal slices: evidence from purine biosensors and P2 receptor agonists and antagonists. Neuropharmacology. 2011;61(1–2):25–34. doi:10.1016/j.neuropharm.2011.02.011
   PubMed Web of Science ®Google Scholar
• Dossi E, Blauwblomme T, Moulard J, et al. Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy. Sci Transl Med. 2018;10(443):443. doi:10.1126/scitranslmed.aar3796
   Web of Science ®Google Scholar
• Dona F, Conceicao IM, Ulrich H, et al. Variations of ATP and its metabolites in the hippocampus of rats subjected to pilocarpine-induced temporal lobe epilepsy. Purinergic Signal. 2016;12(2):295–302. doi:10.1007/s11302-016-9504-9
   PubMed Web of Science ®Google Scholar
• Sebastian-Serrano A, Engel T, de Diego-garcia L, et al. Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation. Hum Mol Genet. 2016;25(19):4143–4156. doi:10.1093/hmg/ddw248
   PubMed Web of Science ®Google Scholar
• Alves M, Gomez-Villafuertes R, Delanty N, et al. Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drug-refractory epilepsy. Epilepsia. 2017;58(9):1603–1614. doi:10.1111/epi.13850
   PubMed Web of Science ®Google Scholar
• Avignone E, Ulmann L, Levavasseur F, Rassendren F, Audinat E. Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J Neurosci. 2008;28(37):9133–9144. doi:10.1523/JNEUROSCI.1820-08.2008
   PubMed Web of Science ®Google Scholar
• Dona F, Ulrich H, Persike DS, et al. Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe epilepsy induced by pilocarpine. Epilepsy Res. 2009;83(2–3):157–167. doi:10.1016/j.eplepsyres.2008.10.008
   PubMed Web of Science ®Google Scholar
• Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A, et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia. 2013;54(9):1551–1561. doi:10.1111/epi.12257
   PubMed Web of Science ®Google Scholar
• Morgan J, Alves M, Conte G, et al. Characterization of the expression of the ATP-gated P2X7 receptor following status epilepticus and during epilepsy using a P2X7-EGFP reporter mouse. Neurosci Bull. 2020;36(11):1242–1258. doi:10.1007/s12264-020-00573-9
   PubMed Web of Science ®Google Scholar
• Kaczmarek-Hajek K, Zhang J, Kopp R, et al. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife. 2018;7. doi:10.7554/eLife.36217
   PubMed Web of Science ®Google Scholar
• Ramirez-Fernandez A, Urbina-Trevino L, Conte G, et al. Deviant reporter expression and P2X4 passenger gene overexpression in the soluble EGFP BAC transgenic P2X7 reporter mouse model. Sci Rep. 2020;10(1):19876. doi:10.1038/s41598-020-76428-0
   PubMed Web of Science ®Google Scholar
• Jimenez-Pacheco A, Diaz-Hernandez M, Arribas-Blazquez M, et al. Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy. J Neurosci. 2016;36(22):5920–5932. doi:10.1523/JNEUROSCI.4009-15.2016
   PubMed Web of Science ®Google Scholar
• Vianna EP, Ferreira AT, Naffah-Mazzacoratti MG, et al. Evidence that ATP participates in the pathophysiology of pilocarpine-induced temporal lobe epilepsy: fluorimetric, immunohistochemical, and Western blot studies. Epilepsia. 2002;43(Suppl 5):227–229. doi:10.1046/j.1528-1157.43.s.5.26.x
   PubMedGoogle Scholar
• Alves M, Smith J, Engel T. Differential expression of the metabotropic P2Y receptor family in the cortex following status epilepticus and neuroprotection via P2Y1 antagonism in mice. Front Pharmacol. 2019;10:1558. doi:10.3389/fphar.2019.01558
   PubMed Web of Science ®Google Scholar
• Sukigara S, Dai H, Nabatame S, et al. Expression of astrocyte-related receptors in cortical dysplasia with intractable epilepsy. J Neuropathol Exp Neurol. 2014;73(8):798–806. doi:10.1097/NEN.0000000000000099
   PubMed Web of Science ®Google Scholar
• Alves M, De Diego Garcia L, Conte G, et al. Context-specific switch from anti- to pro-epileptogenic function of the P2Y1 receptor in experimental epilepsy. J Neurosci. 2019;39(27):5377–5392. doi:10.1523/JNEUROSCI.0089-19.2019
   PubMed Web of Science ®Google Scholar
• Huang C, Chi XS, Li R, et al. Inhibition of P2X7 receptor ameliorates nuclear factor-kappa B mediated neuroinflammation induced by status epilepticus in rat hippocampus. J Mol Neurosci. 2017;63(2):173–184. doi:10.1007/s12031-017-0968-z
   PubMed Web of Science ®Google Scholar
• Mesuret G, Engel T, Hessel EV, et al. P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci Ther. 2014;20(6):556–564. doi:10.1111/cns.12272
   PubMed Web of Science ®Google Scholar
• Glass HC, Shellhaas RA, Wusthoff CJ, et al. Contemporary profile of seizures in neonates: a Prospective Cohort Study. J Pediatr. 2016;174:98–103e101. doi:10.1016/j.jpeds.2016.03.035
   PubMed Web of Science ®Google Scholar
• Soul JS. Acute symptomatic seizures in term neonates: etiologies and treatments. Semin Fetal Neonatal Med. 2018;23(3):183–190. doi:10.1016/j.siny.2018.02.002
   PubMed Web of Science ®Google Scholar
• Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272(5262):735–738. doi:10.1126/science.272.5262.735
   PubMed Web of Science ®Google Scholar
• Menendez Mendez A, Smith J, Engel T. Neonatal seizures and purinergic signalling. Int J Mol Sci. 2020;21(21):7832. doi:10.3390/ijms21217832
   PubMed Web of Science ®Google Scholar
• Fischer W, Franke H, Krugel U, et al. Critical evaluation of P2X7 receptor antagonists in selected seizure models. PLoS One. 2016;11(6):e0156468. doi:10.1371/journal.pone.0156468
   PubMed Web of Science ®Google Scholar
• Nieoczym D, Socala K, Wlaz P. Evaluation of the anticonvulsant effect of brilliant blue G, a selective P2X7 receptor antagonist, in the iv PTZ-, maximal electroshock-, and 6 Hz-induced seizure tests in mice. Neurochem Res. 2017;42(11):3114–3124. doi:10.1007/s11064-017-2348-z
   PubMed Web of Science ®Google Scholar
• Kim JE, Kang TC. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest. 2011;121(5):2037–2047. doi:10.1172/JCI44818
   PubMed Web of Science ®Google Scholar
• Kim JE, Kwak SE, Jo SM, Kang TC. Blockade of P2X receptor prevents astroglial death in the dentate gyrus following pilocarpine-induced status epilepticus. Neurol Res. 2009;31(9):982–988. doi:10.1179/174313209X389811
   PubMed Web of Science ®Google Scholar
• Kim JE, Ryu HJ, Yeo SI, Kang TC. P2X7 receptor regulates leukocyte infiltrations in rat frontoparietal cortex following status epilepticus. J Neuroinflammation. 2010;7(1):65. doi:10.1186/1742-2094-7-65
   PubMedGoogle Scholar
• Kim JE, Ryu HJ, Kang TC. P2X7 receptor activation ameliorates CA3 neuronal damage via a tumor necrosis factor-alpha-mediated pathway in the rat hippocampus following status epilepticus. J Neuroinflammation. 2011;8(1):62. doi:10.1186/1742-2094-8-62
   PubMedGoogle Scholar
• Soni N, Koushal P, Reddy BV, Deshmukh R, Kumar P. Effect of GLT-1 modulator and P2X7 antagonists alone and in combination in the kindling model of epilepsy in rats. Epilepsy Behav. 2015;48:4–14. doi:10.1016/j.yebeh.2015.04.056
   PubMed Web of Science ®Google Scholar
• Amorim RP, Araujo MGL, Valero J, et al. Silencing of P2X7R by RNA interference in the hippocampus can attenuate morphological and behavioral impact of pilocarpine-induced epilepsy. Purinergic Signal. 2017;13(4):467–478. doi:10.1007/s11302-017-9573-4
   PubMed Web of Science ®Google Scholar
• Jamali-Raeufy N, Barati H, Baluchnejadmojarad T, Roghani M, Goudarzi M. Combination therapy with dipeptidyl peptidase-4 and P2X7 purinoceptor inhibitors gives rise to antiepileptic effects in rats. J Chem Neuroanat. 2020;110:101855. doi:10.1016/j.jchemneu.2020.101855
   PubMed Web of Science ®Google Scholar
• Hong S, Xin Y, JiaWen W, et al. The P2X7 receptor in activated microglia promotes depression- and anxiety-like behaviors in lithium -pilocarpine induced epileptic rats. Neurochem Int. 2020;138:104773. doi:10.1016/j.neuint.2020.104773
   PubMed Web of Science ®Google Scholar
• Rozmer K, Gao P, Araujo MGL, et al. Pilocarpine-induced status epilepticus increases the sensitivity of P2X7 and P2Y1 receptors to nucleotides at neural progenitor cells of the juvenile rodent hippocampus. Cereb Cortex. 2017;27(7):3568–3585. doi:10.1093/cercor/bhw178
   PubMed Web of Science ®Google Scholar
• Amhaoul H, Ali I, Mola M, et al. P2X7 receptor antagonism reduces the severity of spontaneous seizures in a chronic model of temporal lobe epilepsy. Neuropharmacology. 2016;105:175–185. doi:10.1016/j.neuropharm.2016.01.018
   PubMed Web of Science ®Google Scholar
• Khan MT, Deussing J, Tang Y, Illes P. Astrocytic rather than neuronal P2X7 receptors modulate the function of the tri-synaptic network in the rodent hippocampus. Brain Res Bull. 2019;151:164–173. doi:10.1016/j.brainresbull.2018.07.016
   PubMed Web of Science ®Google Scholar
• Bedner P, Dupper A, Huttmann K, et al. Astrocyte uncoupling as a cause of human temporal lobe epilepsy. Brain. 2015;138(Pt 5):1208–1222. doi:10.1093/brain/awv067
   PubMedGoogle Scholar
• Illes P, Burnstock G, Tang Y. Astroglia-derived ATP modulates CNS neuronal circuits. Trends Neurosci. 2019;42(12):885–898. doi:10.1016/j.tins.2019.09.006
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim JE. P2 x 7 receptor inhibits astroglial autophagy via regulating FAK- and PHLPP1/2-mediated AKT-S473 phosphorylation following kainic acid-induced seizures. Int J Mol Sci. 2020;21(18).
   Web of Science ®Google Scholar
• Lee DS, Kim JE. Protein disulfide isomerase-mediated S-nitrosylation facilitates surface expression of P2X7 receptor following status epilepticus. J Neuroinflammation. 2021;18(1):14. doi:10.1186/s12974-020-02058-y
   PubMed Web of Science ®Google Scholar
• Sperlagh B, Illes P. P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci. 2014;35(10):537–547. doi:10.1016/j.tips.2014.08.002
   PubMed Web of Science ®Google Scholar
• Xia J, Wang H, Zhang Q, Han Z. Modulation of P2X purinoceptor 3 (P2X3) in pentylenetetrazole-induced kindling epilepsy in rats. Med Sci Monit. 2018;24:6165–6177. doi:10.12659/MSM.910352
   PubMed Web of Science ®Google Scholar
• Alves M, Beamer E, Engel T. The metabotropic purinergic P2Y receptor family as novel drug target in epilepsy. Front Pharmacol. 2018;9:193. doi:10.3389/fphar.2018.00193
   PubMed Web of Science ®Google Scholar
• Avignone E, Lepleux M, Angibaud J, Nagerl UV. Altered morphological dynamics of activated microglia after induction of status epilepticus. J Neuroinflammation. 2015;12(1):202. doi:10.1186/s12974-015-0421-6
   PubMedGoogle Scholar
• Mo M, Eyo UB, Xie M, et al. Microglial P2Y12 receptor regulates seizure-induced neurogenesis and immature neuronal projections. J Neurosci. 2019;39(47):9453–9464. doi:10.1523/JNEUROSCI.0487-19.2019
   PubMed Web of Science ®Google Scholar
• Simoes AP, Silva CG, Marques JM, et al. Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation. Cell Death Dis. 2018;9(3):297. doi:10.1038/s41419-018-0351-1
   PubMedGoogle Scholar
• Alvarez-Ferradas C, Morales JC, Wellmann M, et al. Enhanced astroglial Ca2+ signaling increases excitatory synaptic strength in the epileptic brain. Glia. 2015;63(9):1507–1521. doi:10.1002/glia.22817
   PubMed Web of Science ®Google Scholar
• Nikolic L, Shen W, Nobili P, Virenque A, Ulmann L, Audinat E. Blocking TNFalpha-driven astrocyte purinergic signaling restores normal synaptic activity during epileptogenesis. Glia. 2018;66(12):2673–2683. doi:10.1002/glia.23519
   PubMed Web of Science ®Google Scholar
• Martorell A, Wellmann M, Guiffa F, Fuenzalida M, Bonansco C. P2Y1 receptor inhibition rescues impaired synaptic plasticity and astroglial Ca(2+)-dependent activity in the epileptic hippocampus. Neurobiol Dis. 2020;146:105132. doi:10.1016/j.nbd.2020.105132
   PubMed Web of Science ®Google Scholar
• Beamer E, Lacey A, Alves M, et al. Elevated blood purine levels as a biomarker of seizures and epilepsy. Epilepsia. 2021;62(3):817–828. doi:10.1111/epi.16839
   PubMed Web of Science ®Google Scholar